Sunshine Lake Pharma Co (6887) H1 2025 earnings summary

Executive summary

• Revenue for the first half of 2025 was RMB 1,937.67 million, down 24.9% year-over-year, mainly due to a significant decline in influenza cases impacting core product sales.

• Net profit for the period was RMB 14.65 million, a sharp decrease from RMB 473.43 million in the same period last year.

• Loss and total comprehensive income attributable to equity shareholders was RMB 54.27 million, compared to a profit of RMB 138.63 million last year.

• Gross profit margin remained high at 75.74%, but operating and net profit margins dropped significantly.

Financial highlights

• Gross profit for the period was RMB 1,467.61 million, down 28.1% year-over-year.

• Operating profit was RMB 209.90 million, a 71.5% decrease from the prior year.

• Profit before tax was RMB 95.65 million, down from RMB 607.72 million year-over-year.

• Total assets as of June 30, 2025, were RMB 12,063.45 million; net assets were RMB 4,603.59 million.

• Gearing ratio increased to 101.65%, and quick ratio decreased to 0.77.

• No interim dividend was declared for the period.

Outlook and guidance

• The company aims to enhance capital efficiency, invest in R&D, and expand its product pipeline, focusing on innovative drugs and internationalization.

• Plans include streamlining decision-making, improving operational efficiency, and strengthening global market presence.

• A large-scale biologics facility is expected to be completed in 2026 to support future growth.